Bloomberg reports that Teva has sparked interest as a takeover target.
The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.
The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.
The three drugmakers launched into a series of sell-offs and acquisitions over the weekend.
An insider says Merck may be up for trading its OTC business for Novartis's animal health business, but the benefits for either side may be better on paper.
The company purchased assets from Germany-based Probiodrug.
The finance, electric and broadcasting company has taken a $1-billion interest in DNA technology.
The $2.9 billion deal means Bayer owns prostate cancer drug Xofigo in full.
Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.
The companies are plunking down substantial sums to increase their reach.
The "New Endo" will be one company on the outside, two on the inside.
The prostate cancer drug company is reportedly seeking a buyer to turn things around.
The drug maker is beefing up its MedImmune offerings with a $440-million acquisition and a deal with ADC Therapeutics.
Takeda moves an Alzheimer's treatment to Phase III; Sangamo acquires Ceregene; Catalyst gets breakthrough designation for auto-immune disorder drug; study says seniors likely to opt out of health insurance
Akorn expands, buying Hi-Tech Pharmacal; nursing homes miss their goal to curb antipsychotic-drug use; Bayer cancer drug gets priority review; and Lonza lays off staff
Amgen's newest oncology asset could reach great heights, if the firm can capitalize on its existing commercial and R&D capabilities.
The drug maker is adding Amplimunne's cancer portfolio to subsidiary MedImmune's oncology efforts, one of several recent deals to add heft.
Novartis prepares for a strategic review that hints at scuttling lesser-performing businesses; Regeneron's Eylea sales prompt expansion; Pfizer targets diabetes and obesity; and the FDA approves an MS stem cell trial
Medtronic buys up Cardiocom, Novo will file liraglutide to battle obesity, HHS navigates cutback and looks into anti-psychotic prescription rates, Amgen's Neulasta to compete against Teva's Lonquex.
The drug maker, through its venture fund, took a controlling interest in the digital physician marketing firm.
The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.
Perrigo sweeps Elan off its feet for $8.6 billion, and Valeant is slashing 2,700 jobs.
Onyx says no to Amgen bid, yes to other options; Pfizer/BMS may be able to expand Eliquis appeal; Covidien officially divides into two.
GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.
The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug.
The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.
AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight loss results.
Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M
Why executives evaluating biotech acquisitions shouldn't overlook the cultural dimension: A new paper finds a link to revenue performance.
Already the world's third-largest generics maker, Actavis stands to gain if it can seal the deal